Nicotinic receptors in neurodegeneration

Current Neuropharmacology

Volumn 11, Issue 3, 2013, Pages 298-314

  Posadas, Inmaculada ^a,b   López Hernández, Beatriz ^a,b   Ceña, Valentín ^a,b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Alzheimer disease; Neurodegeneration; Nicotinic receptors; Parkinson disease; Pharmacology; Subunit composition

Indexed keywords

3 (2, 4 DIMETHOXYBENZYLIDENE) ANABASEINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL) ISOXAZOLE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 AMINOBUTYRIC ACID; ALTINICLINE; CITICOLINE; COTININE; DONEPEZIL; DOPAMINE; GALANTAMINE; GLYCINE RECEPTOR; ISPRONICLINE; NICOTINE; NICOTINIC RECEPTOR; PLACEBO; POZANICLINE; RIVASTIGMINE; SEROTONIN; SOFINICLINE; TACRINE; TEBANICLINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; ASTHENIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COGNITION; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; EPILEPSY; FAINTNESS; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; INSOMNIA; MUSCLE SPASM; NAUSEA; NAUSEA AND VOMITING; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION;

EID: 84878664172     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11311030005     Document Type: Review

References (175)

1. Langley, J. N. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J. Physiol. 1905, 33 (4-5), 374-413.
2. Parascandola, J.; Jasensky, R. Origins of the receptor theory of drug action. Bull. Hist Med. 1974, 48 (2), 199-220.
3. Cordero-Erausquin, M.; Marubio, L. M.; Klink, R.; Changeux, J. P. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol. Sci. 2000, 21 (6), 211-217.
4. Millar, N. S.; Gotti, C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology, 2009, 56 (1), 237-246.
5. Galzi, J. L.; Changeux, J. P. Neuronal nicotinic receptors: molecular organization and regulations. Neuropharmacology 1995, 34 (6), 563-582.
6. Moroni, M.; Zwart, R.; Sher, E.; Cassels, B. K.; Bermudez, I. alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacolos06, 70 (2), 755-768.
7. Millar, N. S.; Harkness, P. C. Assembly and trafficking of nicotinic acetylcholine receptors (Review). Mol. Membr. Biol. 2008, 25 (4), 279-292.
8. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 2004, 74 (6), 363-396.
9. Wessler, I.; Kirkpatrick, C. J.; Racke, K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin. Exp. Pharmacol. Physiol. 1999, 26 (3), 198-205.
10. Role, L. W. Diversity in primary structure and function of neuronal nicotinic acetylcholine receptor channels. Curr. Opin. Neurobiol. 1992, 2 (3), 254-262.
11. Drisdel, R. C.; Green, W. N. Neuronal alpha-bungarotoxin receptors are alpha7 subunit homomers. J. Neurosci. 2000, 20 (1), 133-139.
12. Elgoyhen, A. B.; Vetter, D. E.; Katz, E.; Rothlin, C. V.; Heinemann, S. F.; Boulter, J. alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (6), 3501-3506.
13. Itier, V.; Bertrand, D. Neuronal nicotinic receptors: from protein structure to function. FEBS Lett. 2001, 504 (3), 118-125.
14. Newhouse, P. A.; Kelton, M. Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Pharm. Acta Helv. 2000, 74 (2-3), 91-101.
15. Nordberg, A. Nicotinic receptor abnormalities of Alzheimer'sdisease: therapeutic implications. Biol. Psychiatry 2001, 49 (3),200-210.
16. Corringer, P. J.; Le, N. N.; Changeux, J. P. Nicotinic receptors atthe amino acid level. Annu. Rev. Pharmacol. Toxicol. 2000, 40,431-458.
17. Hogg, R. C.; Raggenbass, M.; Bertrand, D. Nicotinic acetylcholinereceptors: from structure to brain function. Rev. Physiol. Biochem.Pharmacol. 2003, 147, 1-46.
18. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal nicotinic acetylcholine receptors: structural revelations,target identifications, and therapeutic inspirations. J. Med. Chem.2005, 48 (15), 4705-4745.
19. Zwart, R.; Vijverberg, H. P. Four pharmacologically distinctsubtypes of alpha4beta2 nicotinic acetylcholine receptor expressedin Xenopus laevis oocytes. Mol. Pharmacol. 1998, 54 (6), 1124-1131.
20. Nelson, M. E.; Kuryatov, A.; Choi, C. H.; Zhou, Y.; Lindstrom, J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholinereceptors. Mol. Pharmacol. 2003, 63 (2), 332-341.
21. Rode, F.; Munro, G.; Holst, D.; Nielsen, E. O.; Troelsen, K. B.; Timmermann, D. B.; Ronn, L. C.; Grunnet, M. Positive allostericmodulation of alpha4beta2 nAChR agonist induced behaviour. Brain Res. 2012, 1458, 67-75.
22. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronalnicotinic receptors. Biochem. Pharmacol. 2009, 78 (7), 703-711.
23. Gotti, C.; Zoli, M.; Clementi, F. Brain nicotinic acetylcholinereceptors: native subtypes and their relevance. Trends Pharmacol.Sci. 2006, 27 (9), 482-491.
24. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in thehuman brain. Prog. Neurobiol. 2000, 61 (1), 75-111.
25. Wada, E.; Wada, K.; Boulter, J.; Deneris, E.; Heinemann, S.; Patrick, J.; Swanson, L. W. Distribution of alpha 2, alpha 3, alpha4, and beta 2 neuronal nicotinic receptor subunit mRNAs in thecentral nervous system: a hybridization histochemical study in therat. J. Comp Neurol. 1989, 284 (2), 314-335.
26. Picciotto, M. R.; Caldarone, B. J.; Brunzell, D. H.; Zachariou, V.; Stevens, T. R.; King, S. L. Neuronal nicotinic acetylcholinereceptor subunit knockout mice: physiological and behavioralphenotypes and possible clinical implications. Pharmacol. Ther.2001, 92 (2-3), 89-108.
27. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi, F.; Zoli, M. Heterogeneity and complexity of native brain nicotinicreceptors. Biochem. Pharmacol. 2007, 74 (8), 1102-1111.
28. Picciotto, M. R.; Zoli, M. Nicotinic receptors in aging anddementia. J. Neurobiol. 2002, 53 (4), 641-655.
29. Gotti, C.; Moretti, M.; Clementi, F.; Riganti, L.; McIntosh, J. M.; Collins, A. C.; Marks, M. J.; Whiteaker, P. Expression ofnigrostriatal alpha 6-containing nicotinic acetylcholine receptors isselectively reduced, but not eliminated, by beta 3 subunit genedeletion. Mol. Pharmacol. 2005, 67 (6), 2007-2015.
30. Turner, J. R.; Kellar, K. J. Nicotinic cholinergic receptors in the ratcerebellum: multiple heteromeric subtypes. J. Neurosci. 2005, 25(40), 9258-9265.
31. Zoli, M.; Lena, C.; Picciotto, M. R.; Changeux, J. P. Identificationof four classes of brain nicotinic receptors using beta2 mutant mice.J. Neurosci. 1998, 18 (12), 4461-4472.
32. Sher, E.; Chen, Y.; Sharples, T. J.; Broad, L. M.; Benedetti, G.; Zwart, R.; McPhie, G. I.; Pearson, K. H.; Baldwinson, T.; De, F. G. Physiological roles of neuronal nicotinic receptor subtypes: newinsights on the nicotinic modulation of neurotransmitter release,synaptic transmission and plasticity. Curr. Top. Med. Chem. 2004,4 (3), 283-297.
33. Baddick, C. G.; Marks, M. J. An autoradiographic survey of mousebrain nicotinic acetylcholine receptors defined by null mutants.Biochem. Pharmacol. 2011, 82 (8), 828-841.
34. Kuryatov, A.; Olale, F.; Cooper, J.; Choi, C.; Lindstrom, J. Humanalpha6 AChR subtypes: subunit composition, assembly, andpharmacological responses. Neuropharmacology 2000, 39 (13),2570-2590.
35. Cui, C.; Booker, T. K.; Allen, R. S.; Grady, S. R.; Whiteaker, P.; Marks, M. J.; Salminen, O.; Tritto, T.; Butt, C. M.; Allen, W. R.; Stitzel, J. A.; McIntosh, J. M.; Boulter, J.; Collins, A. C.; Heinemann, S. F. The beta3 nicotinic receptor subunit: acomponent of alpha-conotoxin MII-binding nicotinic acetylcholinereceptors that modulate dopamine release and related behaviors. J.Neurosci. 2003, 23 (35), 11045-11053.
36. Champtiaux, N.; Han, Z. Y.; Bessis, A.; Rossi, F. M.; Zoli, M.; Marubio, L.; McIntosh, J. M.; Changeux, J. P. Distribution andpharmacology of alpha 6-containing nicotinic acetylcholinereceptors analyzed with mutant mice. J. Neurosci. 2002, 22 (4),1208-1217.
37. Dajas-Bailador, F.; Wonnacott, S. Nicotinic acetylcholine receptorsand the regulation of neuronal signalling. Trends Pharmacol. Sci.2004, 25 (6), 317-324.
38. Wonnacott, S. Presynaptic nicotinic ACh receptors. TrendsNeurosci. 1997, 20 (2), 92-98.
39. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Nicotinic acetylcholine receptors astargets for antidepressants. Mol. Psychiatry 2002, 7 (6), 525-535.
40. Ripoll, N.; Bronnec, M.; Bourin, M. Nicotinic receptors andschizophrenia. Curr. Med. Res. Opin. 2004, 20 (7), 1057-1074.
41. Cahill, A. L.; Hurley, J. H.; Fox, A. P. Coexpression of clonedalpha(1B), beta(2a), and alpha(2)/delta subunits produces noninactivatingcalcium currents similar to those found in bovinechromaffin cells. J. Neurosci. 2000, 20 (5), 1685-1693.
42. Rucktooa, P.; Haseler, C. A.; van, E. R.; Smit, A. B.; Gallagher, T.; Sixma, T. K. Structural Characterization of Binding Mode ofSmoking Cessation Drugs to Nicotinic Acetylcholine Receptorsthrough Study of Ligand Complexes with Acetylcholine-binding Protein. J. Biol. Chem. 2012, 287 (28), 23283-23293.
43. Hefft, S.; Hulo, S.; Bertrand, D.; Muller, D. Synaptic transmissionat nicotinic acetylcholine receptors in rat hippocampal organotypiccultures and slices. J. Physiol 1999, 515 (Pt 3), 769-776.
44. Lena, C.; Changeux, J. P. Role of Ca2+ ions in nicotinic facilitationof GABA release in mouse thalamus. J. Neurosci. 1997, 17 (2),576-585.
45. Levin, E. D. Nicotinic receptor subtypes and cognitive function. J.Neurobiol. 2002, 53 (4), 633-640.
46. Akaike, A.; Tamura, Y.; Yokota, T.; Shimohama, S.; Kimura, J. Nicotine-induced protection of cultured cortical neurons against Nmethyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 1994, 644 (2), 181-187.
47. Shimohama, S.; Akaike, A.; Kimura, J. Nicotine-inducedprotection against glutamate cytotoxicity. Nicotinic cholinergicreceptor-mediated inhibition of nitric oxide formation. Ann. N. Y.Acad. Sci. 1996, 777, 356-361.
48. Hunter, B. E.; de Fiebre, C. M.; Papke, R. L.; Kem, W. R.; Meyer, E. M. A novel nicotinic agonist facilitates induction of long-termpotentiation in the rat hippocampus. Neurosci. Lett. 1994, 168 (1-2), 130-134.
49. Sawada, H.; Shimohama, S.; Tamura, Y.; Kawamura, T.; Akaike, A.; Kimura, J. Methylphenylpyridium ion (MPP+) enhancesglutamate-induced cytotoxicity against dopaminergic neurons incultured rat mesencephalon. J. Neurosci. Res. 1996, 43 (1), 55-62.
50. Cormier, A.; Morin, C.; Zini, R.; Tillement, J. P.; Lagrue, G. Nicotine protects rat brain mitochondria against experimentalinjuries. Neuropharmacology 2003, 44 (5), 642-652.
51. Takeuchi, H.; Yanagida, T.; Inden, M.; Takata, K.; Kitamura, Y.; Yamakawa, K.; Sawada, H.; Izumi, Y.; Yamamoto, N.; Kihara, T.; Uemura, K.; Inoue, H.; Taniguchi, T.; Akaike, A.; Takahashi, R.; Shimohama, S. Nicotinic receptor stimulation protects nigraldopaminergic neurons in rotenone-induced Parkinson's diseasemodels. J. Neurosci. Res. 2009, 87 (2), 576-585.
52. Morens, D. M.; Grandinetti, A.; Reed, D.; White, L. R.; Ross, G.W. Cigarette smoking and protection from Parkinson's disease:false association or etiologic clue? Neurology 1995, 45 (6), 1041-1051.
53. Dajas-Bailador, F. A.; Lima, P. A.; Wonnacott, S. The alpha7nicotinic acetylcholine receptor subtype mediates nicotineprotection against NMDA excitotoxicity in primary hippocampalcultures through a Ca(2+) dependent mechanism. Neuropharmacology 2000, 39 (13), 2799-2807.
54. Kihara, T.; Shimohama, S.; Sawada, H.; Honda, K.; Nakamizo, T.; Shibasaki, H.; Kume, T.; Akaike, A. alpha 7 nicotinic receptortransduces signals to phosphatidylinositol 3-kinase to block A betaamyloid-induced neurotoxicity. J. Biol. Chem. 2001, 276 (17),13541-13546.
55. Liu, Q.; Zhao, B. Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br. J. Pharmacol. 2004, 141 (4), 746-754.
56. Yu, W.; Mechawar, N.; Krantic, S.; Quirion, R. alpha7 Nicotinic receptor activation reduces beta-amyloid-induced apoptosis by inhibiting caspase-independent death through phosphatidylinositol 3-kinase signaling. J. Neurochem. 2011, 119 (4), 848-858.
57. Guan, Z. Z.; Zhang, X.; Mousavi, M.; Tian, J. Y.; Unger, C.; Nordberg, A. Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. J. Neurosci. Res. 2001, 66 (4), 551-558.
58. Takada, Y.; Yonezawa, A.; Kume, T.; Katsuki, H.; Kaneko, S.; Sugimoto, H.; Akaike, A. Nicotinic acetylcholine receptormediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 2003, 306 (2), 772-777.
59. Dani, J. A. Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry 2001, 49 (3), 166-174.
60. Hernan, M. A.; Zhang, S. M.; Rueda-deCastro, A. M.; Colditz, G. A.; Speizer, F. E.; Ascherio, A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann. Neurol. 2001, 50 (6), 780-786.
61. Kawamata, J.; Suzuki, S.; Shimohama, S. alpha7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. Curr. Drug Targets 2012, 13 (5), 623-630.
62. Quik, M.; O'Neill, M.; Perez, X. A. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol. Sci. 2007, 28 (5), 229-235.
63. Bordia, T.; Grady, S. R.; McIntosh, J. M.; Quik, M. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum. Mol. Pharmacol. 2007, 72 (1), 52-61.
64. Huang, L. Z.; Parameswaran, N.; Bordia, T.; Michael, M. J.; Quik, M. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J. Neurochem. 2009, 109 (3), 826-837.
65. Court, J.; Clementi, F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis. Assoc. Disord. 1995, 9 Suppl 2, 6-14.
66. Schroder, H.; de Vos, R. A.; Jansen, E. N.; Birtsch, C.; Wevers, A.; Lobron, C.; Nowacki, S.; Schroder, R.; Maelicke, A. Gene expression of the nicotinic acetylcholine receptor alpha 4 subunit in the frontal cortex in Parkinson's disease patients. Neurosci. Lett. 1995, 187 (3), 173-176.
67. Breese, C. R.; Marks, M. J.; Logel, J.; Adams, C. E.; Sullivan, B.; Collins, A. C.; Leonard, S. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 1997, 282 (1), 7-13.
68. Grady, S. R.; Salminen, O.; Laverty, D. C.; Whiteaker, P.; McIntosh, J. M.; Collins, A. C.; Marks, M. J. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem. Pharmacol. 2007, 74 (8), 1235-1246.
69. Millar, N. S.; Gotti, C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56 (1), 237-246.
70. Zhou, F. M.; Wilson, C. J.; Dani, J. A. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 2002, 53 (4), 590-605.
71. Gotti, C.; Moretti, M.; Bohr, I.; Ziabreva, I.; Vailati, S.; Longhi, R.; Riganti, L.; Gaimarri, A.; McKeith, I. G.; Perry, R. H.; Aarsland, D.; Larsen, J. P.; Sher, E.; Beattie, R.; Clementi, F.; Court JA Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol. Dis. 2006, 23 (2), 481-489.
72. Ryan, R. E.; Ross, S. A.; Drago, J.; Loiacono, R. E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 2001, 132 (8), 1650-1656.
73. Gotti, C.; Guiducci, S.; Tedesco, V.; Corbioli, S.; Zanetti, L.; Moretti, M.; Zanardi, A.; Rimondini, R.; Mugnaini, M.; Clementi, F.; Chiamulera, C.; Zoli, M. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J. Neurosci. 2010, 30 (15), 5311-5325.
74. Jellinger, K. A. Recent developments in the pathology of Parkinson's disease. J. Neural Transm. Suppl 2002, (62), 347-376.
75. Janhunen, S.; Ahtee, L. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. Neurosci. Biobehav. Rev. 2007, 31 (3), 287-314.
76. Livingstone, P. D.; Srinivasan, J.; Kew, J. N.; Dawson, L. A.; Gotti, C.; Moretti, M.; Shoaib, M.; Wonnacott, S. alpha7 and nonalpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci. 2009, 29 (3), 539-550.
77. Dournaud, P.; Delaere, P.; Hauw, J. J.; Epelbaum, J. Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol. Aging 1995, 16 (5), 817-823.
78. Bartus, R. T.; Dean, R. L., III; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217 (4558), 408-414.
79. Nordberg, A.; Winblad, B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 1986, 72 (1), 115-119.
80. Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergmann, K.; Gibson, P. H.; Perry, R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 1978, 2 (6150), 1457-1459.
81. Sahakian, B.; Jones, G.; Levy, R.; Gray, J.; Warburton, D. The effects of nicotine on attention, information processing, and shortterm memory in patients with dementia of the Alzheimer type. Br. J. Psychiatry 1989, 154, 797-800.
82. Guan, Z. Z.; Zhang, X.; Ravid, R.; Nordberg, A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem. 2000, 74 (1), 237-243.
83. Shinotoh, H.; Namba, H.; Fukushi, K.; Nagatsuka, S.; Tanaka, N.; Aotsuka, A.; Ota, T.; Tanada, S.; Irie, T. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann. Neurol. 2000, 48 (2), 194-200.
84. Mechawar, N.; Saghatelyan, A.; Grailhe, R.; Scoriels, L.; Gheusi, G.; Gabellec, M. M.; Lledo, P. M.; Changeux, J. P. Nicotinic receptors regulate the survival of newborn neurons in the adult olfactory bulb. Proc. Natl. Acad. Sci. U. S. A 2004, 101 (26), 9822-9826.
85. Goedert, M.; Spillantini, M. G. A century of Alzheimer's disease. Science 2006, 314 (5800), 777-781.
86. Toyohara, J.; Wu, J.; Hashimoto, K. Recent development of radioligands for imaging alpha7 nicotinic acetylcholine receptors in the brain. Curr. Top. Med. Chem. 2010, 10 (15), 1544-1557.
87. D'Andrea, M. R.; Nagele, R. G. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr. Pharm. Des 2006, 12 (6), 677-684.
88. Bitner, R. S.; Nikkel, A. L.; Markosyan, S.; Otte, S.; Puttfarcken, P.; Gopalakrishnan, M. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res. 2009, 1265, 65-74.
89. Buckingham, S. D.; Jones, A. K.; Brown, L. A.; Sattelle, D. B. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol. Rev. 2009, 61 (1), 39-61.
90. Buccafusco, J. J.; Terry, A. V., Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem. Pharmacol. 2009, 78 (7), 852-862.
91. Buccafusco, J. J.; Beach, J. W.; Terry, A. V., Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther. 2009, 328 (2), 364-370.
92. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. Chem Med Chem. 2007, 2 (6), 746-767.
93. Elrod, K.; Buccafusco, J. J.; Jackson, W. J. Nicotine enhances delayed matching-to-sample performance by primates. Life Sci. 1988, 43 (3), 277-287.
94. Mumenthaler, M. S.; Yesavage, J. A.; Taylor, J. L.; O'Hara, R.; Friedman, L.; Lee, H.; Kraemer, H. C. Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 2003, 28 (7), 1366-1373.
95. Lendvai, B.; Vizi, E. S. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiol. Rev. 2008, 88 (2), 333-349.
96. Mihailescu, S.; Drucker-Colin, R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch. Med. Res. 2000, 31 (2), 131-144.
97. Jones, G. M.; Sahakian, B. J.; Levy, R.; Warburton, D. M.; Gray, J. A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992, 108 (4), 485-494.
98. Min, S. K.; Moon, I. W.; Ko, R. W.; Shin, H. S. Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers. Psychopharmacology (Berl) 2001, 159 (1), 83-88.
99. White, H. K.; Levin, E. D. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl) 1999, 143 (2), 158-165.
100. Bordia, T.; Campos, C.; Huang, L.; Quik, M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2008, 327 (1), 239-247.
101. Holmes, A. D.; Copland, D. A.; Silburn, P. A.; Chenery, H. J. Acute nicotine enhances strategy-based semantic processing in Parkinson's disease. Int. J. Neuropsychopharmacol. 2011, 14 (7), 877-885.
102. Newhouse, P. A.; Potter, A.; Levin, E. D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997, 11 (3), 206-228.
103. Vaglenova, J.; Parameshwaran, K.; Suppiramaniam, V.; Breese, C. R.; Pandiella, N.; Birru, S. Long-lasting teratogenic effects of nicotine on cognition: gender specificity and role of AMPA receptor function. Neurobiol. Learn. Mem. 2008, 90 (3), 527-536.
104. Newhouse, P.; Kellar, K.; Aisen, P.; White, H.; Wesnes, K.; Coderre, E.; Pfaff, A.; Wilkins, H.; Howard, D.; Levin, E. D. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012, 78 (2), 91-101.
105. Benowitz, N. L.; Jacob, P., III Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 1994, 56 (5), 483-493.
106. Echeverria, V.; Zeitlin, R.; Burgess, S.; Patel, S.; Barman, A.; Thakur, G.; Mamcarz, M.; Wang, L.; Sattelle, D. B.; Kirschner, D. A.; Mori, T.; Leblanc, R. M.; Prabhakar, R.; Arendash, G. W. Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice. J. Alzheimers. Dis. 2011, 24 (4), 817-835.
107. Hatsukami, D. K.; Grillo, M.; Pentel, P. R.; Oncken, C.; Bliss, R. Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol. Biochem. Behav. 1997, 57 (4), 643-650.
108. Terry, A. V., Jr.; Hernandez, C. M.; Hohnadel, E. J.; Bouchard, K. P.; Buccafusco, J. J. Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 2005, 11 (3), 229-252.
109. O'Leary, K.; Parameswaran, N.; McIntosh, J. M.; Quik, M. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J. Pharmacol. Exp. Ther. 2008, 325 (2), 646-654.
110. Alkondon, M.; Pereira, E. F.; Cortes, W. S.; Maelicke, A.; Albuquerque, E. X. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 1997, 9 (12), 2734-2742.
111. Jonnala, R. R.; Graham, J. H., III; Terry, A. V., Jr.; Beach, J. W.; Young, J. A.; Buccafusco, J. J. Relative levels of cytoprotection produced by analogs of choline and the role of alpha7-nicotinic acetylcholine receptors. Synapse 2003, 47 (4), 262-269.
112. Sood, A.; Warren, B. J.; Webster, S. J.; Terry, A. V.; Buccafusco, J. J. The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. Neuropharmacology 2007, 53 (5), 588-600.
113. Keowkase, R.; Aboukhatwa, M.; Adam, B. L.; Beach, J. W.; Terry, A. V., Jr.; Buccafussco, J. J.; Luo, Y. Neuroprotective effects and mechanism of cognitive-enhancing choline analogs JWB 1-84-1 and JAY 2-22-33 in neuronal culture and Caenorhabditis elegans. Mol. Neurodegener. 2010, 5, 59.
114. Putignano, S.; Gareri, P.; Castagna, A.; Cerqua, G.; Cervera, P.; Cotroneo, A. M.; Fiorillo, F.; Grella, R.; Lacava, R.; Maddonni, A.; Marino, S.; Pluderi, A.; Putignano, D.; Rocca, F. Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. Clin. Interv. Aging 2012, 7, 113-118.
115. Rolinski, M.; Fox, C.; Maidment, I.; McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane. Database. Syst. Rev. 2012, 3, CD006504.
116. Bond, M.; Rogers, G.; Peters, J.; Anderson, R.; Hoyle, M.; Miners, A.; Moxham, T.; Davis, S.; Thokala, P.; Wailoo, A.; Jeffreys, M.; Hyde, C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol. Assess. 2012, 16 (21), 1-470.
117. Russ, T. C.; Morling, J. R. Cholinesterase inhibitors for mild cognitive impairment. Cochrane. Database. Syst. Rev. 2012, 9, CD009132.
118. Isik, A. T.; Yildiz, G. B.; Bozoglu, E.; Yay, A.; Aydemir, E. Cardiac safety of donepezil in elderly patients with Alzheimer disease. Intern. Med. 2012, 51 (6), 575-578.
119. Giacobini, E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2000, 14 Suppl 1, S3-10.
120. Maelicke, A.; Schrattenholz, A.; Samochocki, M.; Radina, M.; Albuquerque, E. X. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav. Brain Res. 2000, 113 (1-2), 199-206.
121. Samochocki, M.; Zerlin, M.; Jostock, R.; Groot Kormelink, P. J.; Luyten, W. H.; Albuquerque, E. X.; Maelicke, A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl 2000, 176, 68-73.
122. Kihara, T.; Sawada, H.; Nakamizo, T.; Kanki, R.; Yamashita, H.; Maelicke, A.; Shimohama, S. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun. 2004, 325 (3), 976-982.
123. Lopes, C.; Pereira, E. F.; Wu, H. Q.; Purushottamachar, P.; Njar, V.; Schwarcz, R.; Albuquerque, E. X. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J. Pharmacol. Exp. Ther. 2007, 322 (1), 48-58.
124. Schilstrom, B.; Ivanov, V. B.; Wiker, C.; Svensson, T. H. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007, 32 (1), 43-53.
125. Shen, H.; Kihara, T.; Hongo, H.; Wu, X.; Kem, W. R.; Shimohama, S.; Akaike, A.; Niidome, T.; Sugimoto, H. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br. J. Pharmacol. 2010, 161 (1), 127-139.
126. Emre, M.; Aarsland, D.; Albanese, A.; Byrne, E. J.; Deuschl, G.; De Deyn, P. P.; Durif, F.; Kulisevsky, J.; van, L. T.; Lees, A.; Poewe, W.; Robillard, A.; Rosa, M. M.; Wolters, E.; Quarg, P.; Tekin, S.; Lane, R. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 2004, 351 (24), 2509-2518.
127. Finkel, S. I. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Ther. 2004, 26 (7), 980-990.
128. Papke, R. L.; Thinschmidt, J. S.; Moulton, B. A.; Meyer, E. M.; Poirier, A. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br. J. Pharmacol. 1997, 120 (3), 429-438.
129. Arneric, S. P.; Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Anderson, D. J.; Raszkiewicz, J. L.; Hughes, M. L.; Cadman, E. D.; Adams, P.; Garvey, D. S.; (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognitionenhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 1994, 270 (1), 310-318.
130. Decker, M. W.; Curzon, P.; Brioni, J. D.; Arneric, S. P. Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. Eur. J. Pharmacol. 1994, 261 (1-2), 217-222.
131. Wilens, T. E.; Biederman, J.; Spencer, T. J.; Bostic, J.; Prince, J.; Monuteaux, M. C.; Soriano, J.; Fine, C.; Abrams, A.; Rater, M.; Polisner, D. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 1999, 156 (12), 1931-1937.
132. Potter, A.; Corwin, J.; Lang, J.; Piasecki, M.; Lenox, R.; Newhouse, P. A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 1999, 142 (4), 334-342.
133. Terry, A. V., Jr.; Decker, M. W. Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career. Biochem. Pharmacol. 2011, 82 (8), 883-890.
134. Guo, T.; Yang, C.; Guo, L.; Liu, K. A comparative study of the effects of ABT-418 and methylphenidate on spatial memory in an animal model of ADHD. Neurosci. Lett. 2012, 528 (1), 11-15.
135. Buccafusco, J. J.; Terry, A. V., Jr.; Decker, M. W.; Gopalakrishnan, M. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem. Pharmacol. 2007, 74 (8), 1202-1211.
136. Dutta, S.; Hosmane, B. S.; Awni, W. M. Population analyses of efficacy and safety of ABT-594 in subjects with diabetic peripheral neuropathic pain. AAPS J. 2012, 14 (2), 168-175.
137. Rowbotham, M. C.; Duan, W. R.; Thomas, J.; Nothaft, W.; Backonja, M. M. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 2009, 146 (3), 245-252.
138. Decker, M. W.; Bannon, A. W.; Curzon, P.; Gunther, K. L.; Brioni, J. D.; Holladay, M. W.; Lin, N. H.; Li, Y.; Daanen, J. F.; Buccafusco, J. J.; Prendergast, M. A.; Jackson, W. J.; Arneric, S. P. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J. Pharmacol. Exp. Ther. 1997, 283 (1), 247-258.
139. Arneric, S. P.; Holladay, M.; Williams, M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem. Pharmacol. 2007, 74 (8), 1092-1101.
140. Wilens, T. E.; Verlinden, M. H.; Adler, L. A.; Wozniak, P. J.; West, S. A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol. Psychiatry 2006, 59 (11), 1065-1070.
141. Wilens, T. E.; Decker, M. W. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem. Pharmacol. 2007, 74 (8), 1212-1223.
142. Bain, E. E.; Apostol, G.; Sangal, R. B.; Robieson, W. Z.; McNeill, D. L.; Abi-Saab, W. M.; Saltarelli, M. D. A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal nicotinic receptor agonist, in adults with attentiondeficit/ hyperactivity disorder. J. Clin. Psychiatry 2012, 73 (6), 783-789.
143. Kitagawa, H.; Takenouchi, T.; Azuma, R.; Wesnes, K. A.; Kramer, W. G.; Clody, D. E.; Burnett, A. L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003, 28 (3), 542-551.
144. Freedman, R.; Olincy, A.; Buchanan, R. W.; Harris, J. G.; Gold, J. M.; Johnson, L.; Allensworth, D.; Guzman-Bonilla, A.; Clement, B.; Ball, M. P.; Kutnick, J.; Pender, V.; Martin, L. F.; Stevens, K. E.; Wagner, B. D.; Zerbe, G. O.; Soti, F.; Kem, W. R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165 (8), 1040-1047.
145. Wallace, T. L.; Porter, R. H. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem. Pharmacol. 2011, 82 (8), 891-903.
146. Othman, A. A.; Lenz, R. A.; Zhang, J.; Li, J.; Awni, W. M.; Dutta, S. Single-and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. J. Clin. Pharmacol. 2011, 51 (4), 512-526.
147. Tietje, K. R.; Anderson, D. J.; Bitner, R. S.; Blomme, E. A.; Brackemeyer, P. J.; Briggs, C. A.; Browman, K. E.; Bury, D.; Curzon, P.; Drescher, K. U.; Frost, J. M.; Fryer, R. M.; Fox, G. B.; Gronlien, J. H.; Hakerud, M.; Gubbins, E. J.; Halm, S.; Harris, R.; Helfrich, R. J.; Kohlhaas, K. L.; Law, D.; Malysz, J.; Marsh, K. C.; Martin, R. L.; Meyer, M. D.; Molesky, A. L.; Nikkel, A. L.; Otte, S.; Pan, L.; Puttfarcken, P. S.; Radek, R. J.; Robb, H. M.; Spies, E.; Thorin-Hagene, K.; Waring, J. F.; Ween, H.; Xu, H.; Gopalakrishnan, M.; Bunnelle, W. H. Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS. Neurosci. Ther. 2008, 14 (1), 65-82.
148. Hurst, R. S.; Hajos, M.; Raggenbass, M.; Wall, T. M.; Higdon, N. R.; Lawson, J. A.; Rutherford-Root, K. L.; Berkenpas, M. B.; Hoffmann, W. E.; Piotrowski, D. W.; Groppi, V. E.; Allaman, G.; Ogier, R.; Bertrand, S.; Bertrand, D.; Arneric, S. P. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. 2005, 25 (17), 4396-4405.
149. Sharma, G.; Grybko, M.; Vijayaraghavan, S. Action potentialindependent and nicotinic receptor-mediated concerted release of multiple quanta at hippocampal CA3-mossy fiber synapses. J. Neurosci. 2008, 28 (10), 2563-2575.
150. Callahan, P. M.; Hutchings, E. J.; Kille, N. J.; Chapman, J. M.; Terry, A. V., Jr. Positive allosteric modulator of alpha 7 nicotinicacetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 2013, 67, 201-212.
151. Hauser, T. A.; Kucinski, A.; Jordan, K. G.; Gatto, G. J.; Wersinger, S. R.; Hesse, R. A.; Stachowiak, E. K.; Stachowiak, M. K.; Papke, R. L.; Lippiello, P. M.; Bencherif, M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 2009, 78 (7), 803-812.
152. Mazurov, A. A.; Kombo, D. C.; Hauser, T. A.; Miao, L.; Dull, G.; Genus, J. F.; Fedorov, N. B.; Benson, L.; Sidach, S.; Xiao, Y.; Hammond, P. S.; James, J. W.; Miller, C. H.; Yohannes, D. Discovery of (2S,3R)-N-[2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2] oct-3-yl]benzo[b]furan-2-car boxamide (TC-5619), a selective alpha7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. J. Med. Chem. 2012, 55 (22), 9793-9809.
153. Lieberman, J. A.; Dunbar, G.; Segreti, A. C.; Girgis, R. R.; Seoane, F.; Beaver, J. S.; Duan, N.; Hosford, D. A. A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia. Neuropsychopharmacology 2013. Jan 23. doi: 10.1038/npp.2012.259. [Epub ahead of print]
154. Rezvani, A. H.; Eddins, D.; Slade, S.; Hampton, D. S.; Christopher, N. C.; Petro, A.; Horton, K.; Johnson, M.; Levin, E. D. Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: persisting effects on locomotor activity, learning and nicotine selfadministration. Neuroscience 2008, 154 (3), 885-897.
155. Prickaerts, J.; van Goethem, N. P.; Chesworth, R.; Shapiro, G.; Boess, F. G.; Methfessel, C.; Reneerkens, O. A.; Flood, D. G.; Hilt, D.; Gawryl, M.; Bertrand, S.; Bertrand, D.; Konig, G. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012, 62 (2), 1099-1110.
156. Wang, H. Y.; Stucky, A.; Liu, J.; Shen, C.; Trocme-Thibierge, C.; Morain, P. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J. Neurosci. 2009, 29 (35), 10961-10973.
157. Arias, H. R.; Gu, R. X.; Feuerbach, D.; Wei, D. Q. Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor. Biochemistry 2010, 49 (19), 4169-4180.
158. Lilja, A. M.; Porras, O.; Storelli, E.; Nordberg, A.; Marutle, A. Functional interactions of fibrillar and oligomeric amyloid-beta with alpha7 nicotinic receptors in Alzheimer's disease. J. Alzheimers Dis. 2011, 23 (2), 335-347.
159. Haydar, S. N.; Ghiron, C.; Bettinetti, L.; Bothmann, H.; Comery, T. A.; Dunlop, J.; La, R. S.; Micco, I.; Pollastrini, M.; Quinn, J.; Roncarati, R.; Scali, C.; Valacchi, M.; Varrone, M.; Zanaletti, R. SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem. 2009, 17 (14), 5247-5258.
160. Cosford, N. D.; Bleicher, L.; Herbaut, A.; McCallum, J. S.; Vernier, J. M.; Dawson, H.; Whitten, J. P.; Adams, P.; Chavez-Noriega, L.; Correa, L. D.; Crona, J. H.; Mahaffy, L. S.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Santori, E.; Stauderman, K. A.; Whelan, K.; Lloyd, G. K.; McDonald, I. A. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1996, 39 (17), 3235-3237.
161. Vernier, J. M.; El-Abdellaoui, H.; Holsenback, H.; Cosford, N. D.; Bleicher, L.; Barker, G.; Bontempi, B.; Chavez-Noriega, L.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Suto, C.; Washburn, M.; Lloyd, G. K.; McDonald, I. A. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1999, 42 (10), 1684-1686.
162. Schneider, J. S.; Tinker, J. P.; Menzaghi, F.; Lloyd, G. K. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther. 2003, 306 (1), 401-406.
163. Decamp, E.; Schneider, J. S. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res. 2009, 1262, 109-114.
164. Rao, T. S.; Adams, P. B.; Correa, L. D.; Santori, E. M.; Sacaan, A. I.; Reid, R. T.; Cosford, N. D. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist. Brain Res. 2008, 1234, 16-24.
165. The Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006, 66 (3), 408-410.
166. Dunbar, G.; Boeijinga, P. H.; Demazieres, A.; Cisterni, C.; Kuchibhatla, R.; Wesnes, K.; Luthringer, R. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007, 191 (4), 919-929.
167. Obinu, M. C.; Reibaud, M.; Miquet, J. M.; Pasquet, M.; Rooney, T. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26 (5), 913-918.
168. Frolich, L.; Ashwood, T.; Nilsson, J.; Eckerwall, G. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J. Alzheimers Dis. 2011, 24 (2), 363-374.
169. Gatto, G. J.; Bohme, G. A.; Caldwell, W. S.; Letchworth, S. R.; Traina, V. M.; Obinu, M. C.; Laville, M.; Reibaud, M.; Pradier, L.; Dunbar, G.; Bencherif, M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS. Drug Rev. 2004, 10 (2), 147-166.
170. Dunbar, G. C.; Kuchibhatla, R. V.; Lee, G. A randomized doubleblind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J. Psychopharmacol. 2011, 25 (8), 1020-1029.
171. Frolich, L.; Ashwood, T.; Nilsson, J.; Eckerwall, G. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J. Alzheimers Dis. 2011, 24 (2), 363-374.
172. Velligan, D.; Brenner, R.; Sicuro, F.; Walling, D.; Riesenberg, R.; Sfera, A.; Merideth, C.; Sweitzer, D.; Jaeger, J. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr. Res. 2012, 134 (1), 59-64.
173. Lee, C. H.; Zhu, C.; Malysz, J.; Campbell, T.; Shaughnessy, T.; Honore, P.; Polakowski, J.; Gopalakrishnan, M. alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain. Biochem. Pharmacol. 2011, 82 (8), 959-966.
174. Timmermann, D. B.; Sandager-Nielsen, K.; Dyhring, T.; Smith, M.; Jacobsen, A. M.; Nielsen, E. O.; Grunnet, M.; Christensen, J. K.; Peters, D.; Kohlhaas, K.; Olsen, G. M.; Ahring, P. K. Augmentation of cognitive function by NS9283, a stoichiometrydependent positive allosteric modulator of alpha2-and alpha4-containing nicotinic acetylcholine receptors. Br. J. Pharmacol. 2012, 167 (1), 164-182.
175. Andreasen, J. T.; Nielsen, E. O.; Christensen, J. K.; Olsen, G. M.; Peters, D.; Mirza, N. R.; Redrobe, J. P. Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test. J. Psychopharmacol. 2011, 25 (10), 1347-1356.